Boston Scientific's SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter demonstrated strong safety and effectiveness in the FRACTURE trial for severe coronary artery disease. The trial showed a 93.3% rate of freedom from major cardiac events and 93.7% procedural success, with 100% stent delivery success. This device uses acoustic waves to break calcium in arteries, aiding stent placement and improving outcomes. The results support regulatory submissions and could expand treatment options for complex coronary artery disease cases.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Boston Scientific announced a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase, acquiring about 30.4 million shares based on May 15 closing prices. This ASR is part of a larger $5 billion share repurchase authorization, lea...
Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, a company developing innovative cardiovascular implants including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. This i...
Boston Scientific's stock has dropped over 43% year-to-date, wiping out years of gains due to lowered guidance and weakness in key segments like WATCHMAN and Urology. Despite this, a new Buy rating has been initiated, citing achievable guidance after...
